Quest Diagnostics Incorporated
Explore Quest Diagnostics
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
5 leaders · Full leadership timeline
Quest Diagnostics began in 1967 as Metropolitan Pathology Laboratory and has become one of the largest diagnostic information services companies in North America. It serves physicians, hospitals, health plans, employers, consumers, and pharmaceutical partners through lab testing, advanced diagnostics, data, logistics, and patient access infrastructure. The latest audited year shows $11.035B in FY2025 net revenues, $992M in net income attributable to Quest Diagnostics, and nearly 57,000 employees globally. Q1 2026 adds current context: revenue grew 9.2%, organic growth was 9.0%, full-year guidance was raised, and management continued investing in advanced diagnostics, consumer channels, health-system partnerships, and AI-enabled operations.
Quest Diagnostics earns revenue by performing diagnostic tests for physicians, hospitals, consumers, employers, health plans, pharmaceutical companies, and health systems. Revenue depends on requisition volume, revenue per requisition, payer mix, Medicare and commercial reimbursement, acquisitions, patient access, advanced diagnostics, and operating efficiency. The Diagnostic Information Services business is the core revenue engine. Quest also earns smaller Diagnostic Solutions revenue from risk assessment, healthcare IT, employer solutions, and related services. Its scale matters because lab testing has high fixed costs, strict regulation, complex logistics, and reimbursement pressure.
Founder
Brown founded Metropolitan Pathology Laboratory in 1967, establishing the clinical culture and quality focus that would define Quest Diagnostics. He led the company through its MetPath era before the Corning acquisition in 1982.
Chairman and CEO
Freeman led Quest through the 1996 spin-off from Corning and the transformative 1999 SmithKline Beecham Clinical Laboratories acquisition. He established the acquisition-driven growth strategy and public company infrastructure.
Chairman, President, and CEO
Mohapatra expanded Quest's international presence and technology capabilities. He led the company through the AmeriPath acquisition and the 2008-2009 financial crisis, though growth slowed during his tenure.
Chairman, President, and CEO
Rusckowski transformed Quest into a leader in diagnostic information services with strong financial performance. He focused on health system partnerships, operational excellence, advanced diagnostics, and consumer testing. He launched Quest for Health Equity ($100 million commitment) and led the COVID-19 pandemic response. He expanded the board to 40% women and increased diversity.
Chairman, CEO, and President
Davis assumed CEO role in November 2022 and became Chairman in April 2023. He has accelerated the acquisition strategy (LifeLabs, Spectra Laboratories, numerous hospital outreach deals), advanced the AD-Detect Alzheimer's testing platform, industrialized Haystack Oncology MRD testing, and expanded consumer-initiated testing through QuestDirect. He raised 2026 guidance and increased the dividend 7.5% in 2026.
Quest Diagnostics faces reimbursement pressure, PAMA-related Medicare risk, labor and logistics costs, acquisition integration, health-system competition, billing complexity, cybersecurity risk, regulation, and the need to maintain fast, accurate test processing at national scale.
James E. (Jim) Davis is CEO of Quest Diagnostics.
Quest Diagnostics's leadership agenda centers on test menu depth, payer contracts, acquisitions, hospital partnerships, consumer access, and productivity.
Leadership changes help explain shifts in capital allocation, product priorities, risk appetite, and competitive positioning.
Quest Diagnostics's leaders have shaped its expansion, operating model, and response to industry change.